X

Trial Profile

A Double-blind, Randomized Phase II/III Trial of Active Immunotherapy with Globo H-KLH (OPT-822) in Subjects with Metastatic Breast Cancer

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adagloxad simolenin (Primary) ; Cyclophosphamide; OPT 821
Indications Advanced breast cancer
Focus Therapeutic Use
Sponsors OBI Pharma; Optimer Pharmaceuticals

Most Recent Events

09 Sep 2019 Status changed from active, no longer recruiting to completed.
02 Mar 2017 Planned End Date changed from 1 Feb 2017 to 1 Aug 2019.
09 Sep 2016 Planned End Date changed from 1 Dec 2016 to 1 Feb 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com